GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Augmedix Inc (NAS:AUGX) » Definitions » EV-to-Revenue

Augmedix (Augmedix) EV-to-Revenue : 2.64 (As of Apr. 30, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Augmedix EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Augmedix's enterprise value is $118.54 Mil. Augmedix's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $44.86 Mil. Therefore, Augmedix's EV-to-Revenue for today is 2.64.

The historical rank and industry rank for Augmedix's EV-to-Revenue or its related term are showing as below:

AUGX' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.13   Med: 4.2   Max: 10.72
Current: 2.64

During the past 5 years, the highest EV-to-Revenue of Augmedix was 10.72. The lowest was 1.13. And the median was 4.20.

AUGX's EV-to-Revenue is ranked worse than
61.25% of 658 companies
in the Healthcare Providers & Services industry
Industry Median: 1.83 vs AUGX: 2.64

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-30), Augmedix's stock price is $2.83. Augmedix's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.02. Therefore, Augmedix's PS Ratio for today is 2.77.


Augmedix EV-to-Revenue Historical Data

The historical data trend for Augmedix's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Augmedix EV-to-Revenue Chart

Augmedix Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
- - 4.12 1.75 5.89

Augmedix Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.75 2.02 5.28 5.24 5.89

Competitive Comparison of Augmedix's EV-to-Revenue

For the Health Information Services subindustry, Augmedix's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Augmedix's EV-to-Revenue Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Augmedix's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Augmedix's EV-to-Revenue falls into.



Augmedix EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Augmedix's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=118.537/44.855
=2.64

Augmedix's current Enterprise Value is $118.54 Mil.
Augmedix's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $44.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Augmedix  (NAS:AUGX) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Augmedix's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=2.83/1.02
=2.77

Augmedix's share price for today is $2.83.
Augmedix's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.02.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Augmedix EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Augmedix's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Augmedix (Augmedix) Business Description

Traded in Other Exchanges
N/A
Address
111 Sutter Street, Suite 1300, San Francisco, CA, USA, 94104
Augmedix Inc is engaged in ambulatory/clinical/hospital segments of the U.S. patient care services market with products that address medical note documentation needs. The company's products cater to large and small healthcare organizations but can also be adopted by individual practitioners. The company's revenues consist of service fees charged to its customers to subscribe to the company's remote medical documentation and clinical support products.
Executives
Paul Ginocchio officer: Chief Financial Officer C/O AUGMEDIX, INC., 111 SUTTER STREET, SUITE 1300, SAN FRANCISCO CA 94104
Redmile Group, Llc director, 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Margie L. Traylor director 5130 E. CASCALOTE DR, CAVE CREEK AZ 85331
Redco Ii Master Fund, L.p. director, 10 percent owner ONE LETTERMAN DRIVE, BLDG D, STE D3-300, SAN FRANCISCO CA 94129
Robert C. Faulkner director C/O REDMILE GROUP, ONE LETTERMAN DRIVE, BUILDING D, SUITE D, SAN FRANCISCO CA 94129
Roderick H. O'reilly director C/O CHANGE HEALTHCARE INC., 3055 LEBANON PIKE, SUITE 1000, NASHVILLE TN 37214
Mckesson Ventures, Llc director, 10 percent owner ONE POST STREET, SAN FRANCISCO CA 94104
William J Febbo director 600 CALIFORNIA ST., 9TH FLOOR, SAN FRANCISCO CA 94108
Jonathan Hawkins officer: Chief Revenue Officer C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Sandra Breber officer: CHIEF OPERATING OFFICER C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Ian Shakil officer: CHIEF STRATEGY OFFICER C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Emmanuel Krakaris director, officer: PRESIDENT, CEO, AND SECRETARY C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Saurav Chatterjee officer: CHIEF TECHNOLOGY OFFICER C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Laurie Mcgraw director 4720 E COTTON GIN LOOP, SUITE 220, C/O MEDAVAIL HOLDINGS, INC., PHOENIX AZ 85040
Jason Krikorian director, 10 percent owner C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103